证券代码：300204 证券简称：舒泰神 公告编号：2025-028 舒泰神（北京）生物制药股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、舒泰神（北京）生物制药股份有限公司股票交易连续三个交易日（2025 年04月17日、2025年04月18日、2025年04月21日）收盘价格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》等相关规定，属于股票交易异常波动的 情况。 2、经公司董事会核实，截至本公告披露日，公司、控股股东和实际控制人 不存在关于本公司的应披露而未披露的重大事项，在股票异常波动期间不存在买 卖公司股票的行为。 3、风险提示：公司多个在研项目属于创新型生物制品。创新生物医药具有 高科技、高风险、高附加值的特点，从研制、临床试验、报批到投产的周期长、 环节多，容易受到技术、审批、政策等诸多因素影响，面临临床试验进度可能不 如预期、临床试验结果可能不如预期、药品申请上市批准可能不如预期等诸多风 险，请广大投资者谨慎决策，注意投资风险。 一、股票交易异常波动的情况介绍 舒泰神（北京 ...

创新药概念震荡拉升 舒泰神冲击涨停 智通财经4月21日电，舒泰神盘中冲击20CM涨停，迪哲医药、热景生物、锦波生物、迈威生物、海辰 药业等多股涨超5%。消息面上，兴业证券表示，中国创新药企业在研发效率和成本控制上具有明显优 势，能够在较短时间内完成从机制确认到临床前候选化合物的开发，同时临床入组速度也远超国际平均 水平，这不仅加速了新药的上市进程，也为投资者带来了更高的回报潜力。 ...

Group 1: Company Overview and Management Philosophy - The company focuses on innovative drug development for major diseases that significantly impact health, aiming to benefit patients [1] - The management philosophy emphasizes balancing R&D investment with short-term economic benefits to enhance overall company value [1] Group 2: R&D Investment and Financial Performance - R&D investment has decreased by 63.77% year-on-year, raising concerns about the impact on ongoing projects [2] - The company plans to maintain appropriate R&D investment levels to support the advancement of key clinical projects, including STSP-0601, BDB-001, and STSA-1002 [9] Group 3: Clinical Development and Market Potential - STSP-0601 is in clinical research for two indications related to hemophilia, with over 100,000 patients estimated in China, and one-third of severe patients may develop inhibitors [3] - The company has received breakthrough therapy designation for STSP-0601 and plans to submit a conditional marketing application based on positive Phase IIb results [4] - The overseas market strategy currently prioritizes external collaborations for product development [3] Group 4: Financial Strategy and Cash Flow - The company reported a 72.1% improvement in operating cash flow for 2024, attributed to focused R&D investment and enhanced operational efficiency [7] - The current debt-to-asset ratio is low at 23.39%, and the company is considering various financing options, including equity and debt financing, to support R&D and improve cash flow [10] Group 5: Future Outlook and Industry Trends - The company believes in the vast potential of the pharmaceutical industry, driven by the increasing demand for health solutions [10] - There is an openness to various forms of collaboration with domestic and international pharmaceutical companies and investment funds for ongoing projects [8]

北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 关于舒泰神（北京）生物制药股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 2024 年年度股东大会的法律意见书 康达股会字【2025】第 0084 号 为出具本法律意见书，本所律师谨作如下声明： 1、本所律师本次所发表的法律意见，仅依据本法律意见书出具日及以前发生或存 在的事实并基于本所律师对有关法律、法规和规范性文件的理解而形成。在本法律意见 书中，本所律师仅就本次会议的召集和召开程序、出席会议人员的资格、会议的表决程 序和表决结果等事项进行核查和见证后发表法律意见，不对 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-027 舒泰神（北京）生物制药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况，本次股东大会不涉及变 更前次股东大会决议。 2、本次股东大会以现场投票、网络投票相结合的方式召开。 联网投票系统投票的具体时间为：2025 年 04 月 15 日上午 09:15 至下午 15:00 期 间的任意时间。 出席公司 2024 年年度股东大会的股东（或委托代理人）201 人，代表股份 190,443,449 股，占公司有表决权股份总数的 39.8607%。其中，参加现场会议的 股东（或委托代理人）3 人，代表股份 148,170,563 股，占公司有表决权股份总 数的 31.0128%；通过网络投票的股东（或委托代理人）198 人，代表股份 42,272,886 股，占公司有表决权股份总数的 8.8479%。中小投资者 199 人，代表股份 5,582,478 股，占公司有表决权股份总数的 1.1684%。 ...

舒泰神（300204）自2011年4月15日上市以来，已经走过了14个年头。从上市初的33.26亿元市值，到目前的35.79亿 元，公司的市值在这14年里几乎没有显著增长，反映出其在资本市场中的挑战与困境。尽管舒泰神的研发项目和业 务多元化发展，然而近几年业绩的持续下滑让市场对其未来前景保持谨慎态度。 舒泰神上市时的市值为33.26亿元，而目前市值为35.79亿元，市值变化幅度极为有限。这一变化反映了公司在多年未 能实现盈利增长的情况下，资本市场对其未来发展潜力的预期并不乐观。虽然舒泰神依然在推进一些研发项目，并 寄希望于BDB-001等新药的上市，但从现有的财务数据来看，舒泰神能否依靠这些新药实现业绩反转，仍然充满不 确定性。 关键词阅读：舒泰神 分析舒泰神的营业收入和净利润的变化，近五年公司在营收方面持续面临挑战，尤其是两大主力产品的销售收入不 断下滑。苏肽生作为公司历史上具影响力的产品，近年来销售大幅下降，2024年仅实现销售收入1.34亿元，相比高 峰期的12.39亿元，已经出现了萎缩。舒泰清虽然依赖于其在肠道清洁和便秘治疗领域的市场定位，但也受到了集采 等政策影响，面临着价格竞争和市场份额缩水的问题 ...

证券时报·数据宝统计，截至今日上午收盘，上证综指3266.12点，收于年线之上，涨跌幅为0.86%，A股 总成交额为8621.15亿元。到目前为止，今日有317只A股价格突破了年线，其中乖离率较大的个股有金 陵体育、舒泰神、新华都等，乖离率分别为16.72%、11.03%、9.87%；零点有数、聚赛龙、泓淋电力等 个股乖离率较小，刚刚站上年线。 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 300651 | 金陵体 育 | 19.98 | 17.73 | 13.22 | 15.43 | 16.72 | | 300204 | 舒泰神 | 11.33 | 3.17 | 6.99 | 7.76 | 11.03 | | 002264 | 新华都 | 10.09 | 1.27 | 5.76 | 6.33 | 9.87 | | 000823 | 超声电 子 | 9.99 | 1.80 | 9.04 | 9 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-026 舒泰神（北京）生物制药股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）第六届董事会第 六次会议审议通过了《关于提请召开公司2024年年度股东大会的议案》，本次股东 大会将于2025年04月15日采用现场表决与网络投票相结合的方式召开。《关于召开 2024年年度股东大会的通知》已于2025年03月25日刊登于中国证监会指定的创业板 信息披露网站。现将会议有关事项提示如下： 一、召开会议的基本情况 1、股东大会届次：2024年年度股东大会。 2、股东大会召集人：舒泰神（北京）生物制药股份有限公司董事会。 3、会议召开的合法、合规性：公司第六届董事会第六次会议审议通过了《关于 提请召开公司2024年年度股东大会的议案》，决定召开股东大会，召集程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开日期和时间： （1）现场会议召开时间为：2025年04月15日 ...

Core Viewpoint - Shuyat's financial performance continues to decline, with a revenue drop of 10.81% year-on-year and a net loss of 144.8 million yuan, marking the fifth consecutive year of losses [1][2] Financial Performance - In 2024, Shuyat reported total revenue of 325 million yuan, down from the previous year [1] - The net loss for the year was 144.8 million yuan, although this represents a 63.69% reduction in losses compared to the prior year [1] Research and Development - The company's R&D investment plummeted by 63.77% to 162 million yuan, indicating a significant cutback that may alleviate losses in the short term but raises concerns about innovation [2] - The lack of new drug development has been highlighted, with core products contributing over 96% of revenue despite being on the market for nearly 20 years [2] Product Challenges - The flagship product, Sutai Sheng, has faced severe challenges, including removal from the medical insurance list and a dramatic sales drop from over 1.2 billion yuan in 2019 to only 1.16 million units in 2024 [3] - Efforts to expand indications for Sutai Sheng have been hindered by slow clinical trial progress and missing data [3] Market Dynamics - Shuyat's other key product, Shuyat Qing, accounted for 55% of revenue but operates in a market with a total size of less than 1 billion yuan, facing price competition from similar products [4] - Sales revenue for Shuyat Qing fell by 8.2% year-on-year to 179 million yuan, indicating limited growth potential [4] Industry Implications - The situation at Shuyat reflects broader industry risks associated with reliance on a single product, especially in the context of medical insurance cost control and centralized procurement [5] - Experts warn that without accelerated new drug development or strategic acquisitions, Shuyat may face delisting [5] Conclusion - Shuyat's decline from a leading position in the nerve growth factor market to facing high delisting risks serves as a cautionary tale for the industry, emphasizing the necessity of innovation for survival [6]

Core Viewpoint - In 2024, Shuyou Shen reported a decline in revenue and an increase in losses, with significant changes in executive compensation structures [1][3]. Financial Performance - The company achieved a revenue of 325 million yuan in 2024, representing a year-on-year decrease of 10.81% compared to 364 million yuan in 2023 [2]. - The net profit attributable to shareholders was -144.84 million yuan, indicating a worsening loss compared to -398.89 million yuan in the previous year, a 63.69% improvement in loss [2]. - Research and development expenses amounted to 162 million yuan, accounting for 49.97% of total revenue, which is a 63.77% decrease from the previous year [1][2]. Product Performance - The product "Shuyouqing" generated sales of 179 million yuan, making up 55.16% of total revenue, down 8.20% year-on-year [2]. - "Sutai" contributed 134 million yuan in sales, representing 41.21% of total revenue, with a decline of 17.30% compared to the previous year [2]. - The product "Shusitong" contributed 7.71 million yuan in revenue after being included in the 2023 National Medical Insurance Directory [2]. Executive Compensation - In 2024, the chairman Zhou Zhiwen received a total pre-tax compensation of 1.1661 million yuan, while the general manager Wang Chao's compensation was 1.5433 million yuan, which is higher than that of the chairman [3][4].